469 related articles for article (PubMed ID: 28362068)
21. Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana.
Villa G; Phillips RO; Smith C; Stockdale AJ; Beloukas A; Appiah LT; Chadwick D; Ruggiero A; Sarfo FS; Post F; Geretti AM
J Infect; 2018 Jun; 76(6):515-521. PubMed ID: 29702139
[TBL] [Abstract][Full Text] [Related]
22. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
[TBL] [Abstract][Full Text] [Related]
23. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
24. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Boyd A; Lasnier E; Molina JM; Lascoux-Combe C; Bonnard P; Miailhes P; Wendum D; Meynard JL; Girard PM; Lacombe K
Antivir Ther; 2010; 15(7):963-74. PubMed ID: 21041911
[TBL] [Abstract][Full Text] [Related]
25. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection.
Tsai WC; Hsu WT; Liu WD; Sun HY; Chuang YC; Huang YS; Cheng A; Lin KY; Huang YC; Chen GJ; Huang SH; Sheng WH; Hsieh SM; Hung CC; Chang SC
Liver Int; 2019 Aug; 39(8):1408-1417. PubMed ID: 30712284
[TBL] [Abstract][Full Text] [Related]
26. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Matthews GV; Cooper DA; Dore GJ
Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
[TBL] [Abstract][Full Text] [Related]
27. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J
J Acquir Immune Defic Syndr; 2020 Aug; 84(5):527-533. PubMed ID: 32692112
[TBL] [Abstract][Full Text] [Related]
28. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
[TBL] [Abstract][Full Text] [Related]
29. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort.
Dezanet LNC; Kassime R; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
Clin Infect Dis; 2022 Mar; 74(6):1012-1021. PubMed ID: 34197574
[TBL] [Abstract][Full Text] [Related]
30. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.
Boyd A; Lacombe K; Lavocat F; Maylin S; Miailhes P; Lascoux-Combe C; Delaugerre C; Girard PM; Zoulim F
J Hepatol; 2016 Oct; 65(4):683-691. PubMed ID: 27210429
[TBL] [Abstract][Full Text] [Related]
31. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Pradat P; Le Pogam MA; Okon JB; Trolliet P; Miailhes P; Brochier C; Maynard M; Bailly F; Zoulim F; Cotte L
J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650
[TBL] [Abstract][Full Text] [Related]
32. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
Boyd A; Piroth L; Maylin S; Maynard-Muet M; Lebossé F; Bouix C; Lascoux-Combe C; Mahjoub N; Girard PM; Delaugerre C; Carrat F; Lacombe K; Miailhes P
J Viral Hepat; 2016 Dec; 23(12):1017-1026. PubMed ID: 27486094
[TBL] [Abstract][Full Text] [Related]
33. Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy.
Avihingsanon A; Apornpong T; Ramautarsing RA; Ubolyam S; Tangkijvanich P; Ananworanich J; Lange JM; Matthews G; Lewin SR; Ruxrungtham K;
Antivir Ther; 2014; 19(1):41-9. PubMed ID: 23970149
[TBL] [Abstract][Full Text] [Related]
34. Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.
Archampong T; Ojewale O; Bears K; Chen Y; Lartey M; Sagoe KW; Obo-Akwa A; Gong Y; Langaee T; Kwara A
J Acquir Immune Defic Syndr; 2019 Dec; 82(4):421-425. PubMed ID: 31335591
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
[TBL] [Abstract][Full Text] [Related]
36. HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa.
Maponga TG; Andersson MI; van Rensburg CJ; Arends JE; Taljaard J; Preiser W; Glashoff RH
BMC Infect Dis; 2018 May; 18(1):214. PubMed ID: 29739341
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus sequencing and liver fibrosis evaluation in HIV/HBV co-infected Nigerians.
Grant J; Agbaji O; Kramvis A; Yousif M; Auwal M; Penugonda S; Ugoagwu P; Murphy R; Hawkins C
Trop Med Int Health; 2017 Jun; 22(6):744-754. PubMed ID: 28376292
[TBL] [Abstract][Full Text] [Related]
39. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.
Petersen J; Heyne R; Mauss S; Schlaak J; Schiffelholz W; Eisenbach C; Hartmann H; Wiese M; Boeker K; Loehr HF; John C; Leuschner M; Trautwein C; Felten G; Trein A; Krause W; Ruppert S; Warger T; Hueppe D
Dig Dis Sci; 2016 Oct; 61(10):3061-3071. PubMed ID: 26576555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
